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Abstract
Transgenic rats with inducible expression of the mouse Ren2 gene were used to elucidate mechanisms leading to the
development of hypertension and renal injury. Ren2 transgene activation was induced by administration of a naturally
occurring aryl hydrocarbon, indole-3-carbinol (100 mg/kg/day by gastric gavage). Blood pressure and renal parameters
were recorded in both conscious and anesthetized (butabarbital sodium; 120 mg/kg IP) rats at selected time-points during
the development of hypertension. Hypertension was evident by the second day of treatment, being preceded by reduced
renal sodium excretion due to activation of the thiazide-sensitive sodium-chloride co-transporter. Renal injury was evident
after the first day of transgene induction, being initially limited to the pre-glomerular vasculature. Mircoalbuminuria and
tubuloinsterstitial injury developed once hypertension was established. Chronic treatment with either hydrochlorothiazide
or an AT1 receptor antagonist normalized sodium reabsorption, significantly blunted hypertension and prevented renal
injury. Urinary aldosterone excretion was increased ,20 fold, but chronic mineralocorticoid receptor antagonism with
spironolactone neither restored natriuretic capacity nor prevented hypertension. Spironolactone nevertheless ameliorated
vascular damage and prevented albuminuria. This study finds activation of sodium-chloride co-transport to be a key
mechanism in angiotensin II-dependent hypertension. Furthermore, renal vascular injury in this setting reflects both
barotrauma and pressure-independent pathways associated with direct detrimental effects of angiotensin II and
aldosterone.
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Introduction
Hypertension is a major world health problem associated with a
substantial cost, in terms of patient mortality/morbidity and
economic burden. Tremendous strides have been made in this
field and there are several treatments for reducing blood pressure
in most patients. Nevertheless, basic research to establish causal
pathways may lead to more effective management of existing
hypertension or importantly provide a foundation for life-style
advice in the pre-hypertensive phase. This endeavor is facilitated
by the use of appropriate animal models. One such model is the
cyp1a1-Ren2 transgenic rat (TGR) in which hypertension can be
reversibly induced, without surgical intervention, by dietary
administration of the non-toxic, naturally occurring (for example
in brassicas) aryl hydrocarbon, indole-3-carbinol (I3C) [1]. An
advantage of this model is that changing the dose of I3C
administered can alter the severity of hypertension. This allows,
for instance, the generation of a slowly-developing hypertension,
analogous to chronic infusion of subpressor doses of angiotensin II
[2,3] or malignant hypertension (MH), characterized by rapidly
accelerating blood pressure and injury to target organs [4].
In the cyp1a1-Ren2 rat, a transgene has been integrated into the Y
chromosome. This transgene places mouse Ren2 cDNA expression
under the control of an inducible cytochrome p450-1a1 promotor
[1]. Expression of Ren2, primarily in the liver, leads to increased
circulating renin levels, activation of the renin-angiotensin-aldoste-
rone system and a rise in blood pressure. This rise in pressure is
accompanied by a sustained elevation of circulating renin.
Intrarenal synthesis of angiotensin II [5,6], promoted by elevated
renin and pro-renin receptor expression [7], contributes to the
pathology of hypertension in the cyp1a1-Ren2 rat, and the model is
therefore complementary to approaches using chronic infusion of
angiotensin II, in which renin activity is suppressed.
The current study was designed to resolve key mechanisms
leading to hypertension in the cyp1a1-Ren2 TGR and focuses on
sodium transport in the distal convoluted tubule. Several lines of
evidence led us to hypothesize that hypertension in the TGR
model originates in the kidney and reflects an impaired ability to
excrete sodium. First, dietary sodium loading exacerbates
hypertension [5]. Second, renal blood flow is attenuated [4],
pressure natriuresis is impaired [8] and tubuloglomerular feedback
is activated [9], whilst third, the systemic hormonal profile of
elevated angiotensin II and aldosterone would reduce natriuretic
capacity by effects on the tubule epithelium [10,11,12,13] and
medullary vasa recta [14]. Our hypothesis is further supported by
the observation that manoeuvers improving renal blood flow and/
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activation [15,16].
We find that induction of hypertension in the cyp1a1-Ren2 TGR
causes sustained activation of the thiazide-sensitive co-transporter
by angiotensin II in the distal tubule. Renal injury is predom-
inantly vascular, precedes the development of hypertension and
may involve mineralocorticoid-dependent pathways.
Results
Systolic blood pressure and diastolic blood pressure increased
significantly during the 24 hours following the second dose of I3C
(Figure 1). Over the experimental time-course, systolic increased
proportionally more than diastolic blood pressure and pulse
pressure was therefore increased. Heart rate fell significantly
during the period of transgene induction, consistent with an intact
baroreceptor reflex. The day-night cycle of locomotor activity was
unaffected by RAAS activation. The statistically significant
periodicity of blood pressures, heart rate and activity was
approximately circadian during the baseline period. Analysis was
performed on de-trended data from the hypertensive period and
persistency of circadian rhythmicity was observed.
Activation of the cyp1a1-Ren2 transgene promotes anti-
natriuresis
Under anaesthesia, we observed a progressive increase in mean
arterial blood pressure (Figure 2A, ANOVA P,0.001) with
Figure 1. Telemetry data from Cyp1a1-Ren2 transgenic rats. Recordings were made in rats (n=5) over a baseline period and following 7
consecutive days of indole-3-carbinol administration (I3C; Shaded area). A) locomotor activity; B) Blood pressure (BP), with systolic as a solid line and
diastolic as a dashed line and C) HR. Data are hourly means, smoothed with a 5-point rolling average and shown without error bars for clarity. The
vertical lines represent the midnight time point. I3C was administered at 10am.
doi:10.1371/journal.pone.0036311.g001
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observed on day 2 of Ren2 induction. Glomerular filtration rate
rose significantly, at least until day 4 (Figure 2B; ANOVA P,0.01)
but then fell back to control levels. Effective renal plasma flow
(Table 1) was stable. In consequence, filtration fraction was
elevated only on day 4 and renal vascular resistance only on day
8(Table 1). Transgene induction reduced natriuretic capacity
(Figure 2C; ANOVA P,0.001), with sodium excretion falling to
,50% of control values by day 2. There was a significant linear
trend toward hypokalaemia (P,0.05), despite which fractional
potassium excretion remained robust (Table 1).
Fractional sodium excretion fell (Table 1) with transgene
induction, indicating a tubular origin for the antinatriuresis. We
attempted to localize this effect by measuring the fractional
excretion of lithium excretion (Figure 2D). This was initially
elevated (ANOVA P,0.01), indicating diminution of proximal
tubular reabsorption and localizing the antinatriuretic effect to
more distal nephron segments.
In conscious rats, sodium intake (initially 2.3860.11 mmol/
24 h), declined over the induction period but this was not
statistically significant until the final day (1.3860.17 mmol/24 h;
P,0.01). Body weight was found not to change significantly, with
end-weight being 96.561.2% of start weight. 24 h urinary
aldosterone excretion was increased ,20 fold over the induction
period (Figure 3 ANOVA P,0.001) and we therefore focused our
experiments on the aldosterone-sensitive distal nephron (ASDN).
Sodium-chloride co-transport (NCC, Slc12a3) and the epithelial
sodium channel (ENaC, Scnn1) account for the majority of sodium
transport in the ASDN and the contribution of each was assessed
pharmacologically. At baseline, thiazide-sensitive transport was
responsible for the reabsorption of ,5% of the filtered sodium
load. This increased progressively during Ren2-transgene induction
(Figure 4A; ANOVA P,0.01), as did abundance of total NCC
protein relative to GAPDH (Figure 4B; ANOVA P,0.001). A
positive correlation (Pearson r=0.60; P,0.01) was observed
between NCC protein abundance and thiazide-sensitive sodium
reabsorption. An amiloride-sensitive pathway reabsorbed ,2% of
the filtered sodium in non-induced rats. There was a slight initial
increase in both amiloride-sensitive sodium reabsorption
(Figure 4C) and in the abundance of aENaC relative to GAPDH
(Figure 4D). Although neither reached statistical significance, both
sets of data suggest a similar trend- a transient rise, with both back
to baseline by day 8.
The role of NCC-mediated sodium reabsorption was assessed
by chronically administering thiazide during transgene induction.
The blood pressure increase was significantly attenuated
(Figure 4E), but still remained significantly higher than control
animals. The partial rescue of the hypertensive phenotype was
associated with a large increase in fractional sodium excretion
(Figure 4F). An acute bolus of hydrochlorothiazide produced no
Figure 2. Renal function in anaethetized rats. A) mean arterial blood pressure (MABP); B) glomerular filtration rate (GFR); C) urinary sodium
excretion and D) the fractional excretion of lithium. Measurements were made in cyp1a1-Ren2 transgenic rats, on either day 2 (n=9), 4 (n=9) or 8
(n=9) in the induction regimen. Non-induced rats (n=8) served as control. Data are mean 6 SE. Statistical comparisons were made using ANOVA
with Bonferroni post-test. ***P,0.001, **P,0.01, *P,0.05 versus the control group.
doi:10.1371/journal.pone.0036311.g002
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blockade was complete at the chronic infusion level.
Activation of the cyp1a1-Ren2 transgene causes
microvascular injury
Modest albuminuria developed over the experimental time-
course (Figure 5; ANOVA P,0.001) and kidneys were therefore
examined for microvascular injury. An ordered categorical scoring
of microvascular injury indicated a significant (X
2 analysis;
P=0.028) contingency between the duration of transgene
induction and microvascular injury. After 1 day of treatment,
medial myocyte vacuolation was evident in arcuate and the larger
interlobular arteries, indicative of vasospasm (Figure 6A). There
was also rare focal medial myocyte cell death (Figure 6B). No such
injury was observed in the control group. In rats studied at day 4,
vascular damage was both more prevalent and severe, with foci of
confluent medial myocyte death, apoptotic nuclear fragments and
hemorrhage into the necrotic foci (Figure 6C). There was low-
grade mononuclear cell infiltration into the perivascular adventi-
tia. By day 8, the destructive vascular injury was more extensive
still (Figure 6D), and fibroid necrosis was also evident in smaller
interlobular arteries and afferent arterioles, consistent with our
previous data [4]. Areas of tubuloinsterstitial injury were also
observed, which were small and localized mainly in the cortex.
There was no histological evidence of malignant phase hyperten-
sion, such as ‘‘onion-skinning’’ of the renal arterioles.
Effect of spironolactone or losartan on blood pressure,
renal function an microvascular injury
Chronic administration of losartan blunted the hypertensive
response to transgene induction (Figure 7A), increased fractional
sodium excretion (Ren2 induction alone=0.1560.03% versus co-
administration of losartan=0.4060.04; P,0.01) and normalized
thiazide-sensitive sodium reabsorption (Figure 7B). Kidneys from
three of these rats were examined histologically and there was no
evidence of hypertensive vascular injury. Spironolactone had no
antihypertensive effect (Figure 7A) and nor did it have any effect
on thiazide-sensitive sodium reabsorption (Figure 7B). Mineralo-
corticoid receptor blockade did, however, prevent the develop-
ment of albuminuria during transgene induction (albumin
excretion in mg/24 h) Ren2 induction alone=1.1660.12; Ren2
induction with co-administration of spironolactone=0.1860.07;
P,0.01). Kidneys from five spironolactone treated rats were
examined histologically: in two cases there was no evidence of
vascular injury; in the other three, variable fibroid necrosis was
observed.
Discussion
In this study we investigated the early renal adaptation to RAAS
activation in the cyp1a1-Ren2 TGR. We show that the early phase
of hypertension, characterized in this model by circulating
angiotensin II in the high physiological range [5], is associated
with impaired natriuresis due to activation of the thiazide-sensitive
sodium-chloride cotransporter, with little contribution from
amiloride-sensitive sodium transport.
Hypertension, sodium reabsorption and thiazide-
sensitive co-transport
The synergistic effect of angiotensin II and sodium intake on
blood pressure has long been known but underlying mechanisms
are not fully understood. Angiotensin II promotes sodium
retention and volume expansion, particularly if sodium intake is
high [17,18,19]. However, a strong correlation between sodium
balance and blood pressure is not a consistent feature [19,20],
perhaps because increased renal arterial pressure can stimulate
natriuresis [21]. Sustained hypertension may also reflect salt-
induced sensitization of the sympathetic nervous system [22] and
vascular smooth muscle [23] to angiotensin II.
Previous studies in cyp1a1-Ren2 TGR have demonstrated that
hypertension is associated with enhanced sodium reabsorption [6]
and the rise in blood pressure is aggravated by dietary sodium-
loading [5]. In the current study, sodium intake was lower by
,10% over days 1–4 of transgene induction and reduced by 40%
by the final day. This might contribute to a reduced sodium
excretion, particularly in rats studied after 8 days of hypertension.
Table 1. Renal data and plasma electrolytes in cyp1a1-Ren2
transgenic rats before and after the induction of
hypertension.
Control Day 2 Day 4 Day 8 ANOVA
n 8 998
Body weight (g) 324614 318616 343613 305613 NS
FENa (%) 0.3960.06 0.1660.03
** 0.1560.03
** 0.0960.02
** ,0.001
FEK (%) 38.064.5 30.362.9 31.762.2 30.069.4 NS
V( ml/min) 9.860.7 13.663.5 13.261.0 9.362.0 NS
PNa (mmol/l) 135.960.4 134.360.7 134.060.6 132.6.361.7 =0.059
PK (mmol/l) 4.2360.06 4.1060.12 4.0360.11 3.8760.09 NS
Hct (%) 46.561.0 48.360.5 48.761.0 52.061.1
** ,0.01
eRPF (ml/min) 6.7 6 0.6 8.360.8 7.260.4 7.661.0 NS
RBF (ml/min) 12.760.7 16.061.3 14.060.7 16.162.1 NS
FF (%) 28.461.6 29.862.2 37.062.0
** 20.061.5
* ,0.01
RVR
(mmHg.ml.min21)
10.560.6 9.760.8 12.460.6 14.461.3
* ,0.01
Data are mean6 SE. Comparisons were made using one-way ANOVA (P value
shown in column), with Bonferroni post-hoc test: *=P,0.05, **=P,0.01. FENa
and FEK indicates the fractional excretion of sodium and potassium; V is urine
flow rate; PNa and PK are the plasma concentration of sodium and potassium;
Hct is hematocrit; eRPF and RBF are effective renal plasma and blood flow,
respectively; FF is filtration fraction and RVR is renal vascular resistance.
doi:10.1371/journal.pone.0036311.t001
Figure 3. 24-hour urinary excretion of aldosterone. Urine was
collected from conscious cyp1a1-Ren2 transgenic rats (n=8) maintained
in individual metabolism cages, over consecutive days of transgene
induction. Data are mean 6 SE. Statistical comparisons were made
using ANOVA with Bonferroni post-test. ***P,0.001, **P,0.01 versus
the control day.
doi:10.1371/journal.pone.0036311.g003
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(DthiazideNa); B) the expression of the thiazide-sensitive co-transporter protein (NCC) in whole kidney extracts, normalized to that of GAPDH; C)
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studies plasma sodium was not changed. In this setting we
observed an impaired capacity to excrete an intravenous saline
load. In the proximal tubule, angiotensin II exerts a biphasic effect
on sodium transport, becoming inhibitory at high concentrations
[24,25]. In our study, the increase in fractional lithium excretion
observed at days 2 and 4 indicates a reduction in proximal tubule
sodium reabsorption [26] and localizes the antinatriuresis to more
distal nephron segments. Since mice infused chronically with
angiotensin II display increased sodium reabsorption in the ASDN
[27], we probed the function of this region with inhibitors of the
major pathways for sodium transport, ENaC and NCC. Both
angiotensin II and aldosterone can stimulate ENaC activity
[13,28] but we found the amiloride-sensitive pathway small and
not greatly influenced by transgene induction. There was perhaps
a trend towards an increase in both amiloride-sensitive transport
and aENaC protein abundance but this normalized by day 8. Our
protocol ultimately causes malignant hypertension after ,14 days
[4]. In contrast, when induction is aimed at producing a non-
malignant stable hypertension, chronic amiloride treatment causes
a transiently negative sodium balance and abolishes hypertension
in cyp1a1-Ren2 TGR [3], even though ENaC mRNA levels do not
change. It is plausible that that modest increases in angiotensin II
activate existing pools of ENaC and the resulting increase in blood
pressure is amiloride-sensitive. However, when angiotensin II
levels are increased further, a sustained increase in NCC activity is
observed. The increased sodium reabsorption in the DCT would
reduce sodium delivery to the collecting duct and thereby limit
amiloride-sensitive sodium transport. Under such circumstances,
hypertension would be expected to be mainly thiazide-sensitive
(Figure 4E). The thiazide-resistant component in the present study
was small (Figure 4E) and may be due to the transiently increased
ENaC activity, uncovered when NCC is inhibited.
Thiazides are considered to be selective inhibitors of transport
by NCC, but recently it has been shown that they also inhibit
sodium reabsorption through Slc4A8 in the collecting duct [29].
However, the strong positive correlation between NCC abun-
dance and thiazide-sensitive sodium reabsorption suggests that
transport through Slc4A8 plays only a minor role in our studies.
In order to be physiologically active, NCC must be phosphor-
ylated on threonine and serine residues in a regulatory domain in
the N-terminus [30,31], and it must be correctly trafficked to the
apical membrane of the DCT. In our study, we did not measure
NCC phosphorylation or define localization to a specific sub-
cellular compartment. Measurements of NCC phosphorylation
are increasingly used as a surrogates for those of transport, yet
evidence suggests that although phosphorylation is necessary, it is
not sufficient, to explain transport activation in cation-chloride co-
transporters [32]. Thus, we consider that the increase in total
NCC expression, which paralleled the blood pressure rise, was
more than sufficient to account for the increased thiazide-sensitive
sodium reabsorption observed.
Previous studies have shown that both angiotensin II and
aldosterone can independently increase NCC-mediated sodium
transport in the DCT [12,33,34,35,36]. Our data show that the
activation of NCC occurs via AT1R as losartan caused a
natriuresis and fully normalized NCC activity. In contrast,
spironolactone, at levels sufficient to achieve complete mineralo-
corticoid receptor blockade [37], had no effect on thiazide-
sensitive sodium reabsorption or blood pressure. MR activation
does not therefore appear to be major factor in our model,
consistent with some previous studies [3,6,27], but contrasting with
others [38]. It is also reported that hypertension per se reduces
NCC expression in the apical membrane of the DCT [39]. We
cannot discount a countervailing influence of hypertension on
NCC activity, but our data indicate that the overall outcome was
an angiotensin II-mediated increase in thiazide-sensitive sodium
transport.
Chronic infusion of either hydrochlorothiazide or losartan was
an effective antihypertensive measure. Both treatments also
increased fractional sodium excretion, implying that renal sodium
retention is a key hypertensive mechanism in this model. In
support of this hypothesis, reciprocal transplantation studies in
AT1AR null and wild-type mice show that renal AT1R mediate
the chronic hypertensive effects of angiotensin II infusion by
promoting renal sodium reabsorption [40]. However, in our study
there was a trend towards volume contraction as blood pressure
rose, suggesting that the effects of angiotensin II and dietary salt on
blood pressure do not necessarily reflect volume expansion here
[19,20]. Indeed, other studies indicate that the antihypertensive
effect of thiazide diuretics in angiotensin II-dependent hyperten-
sion is not exclusively related to depletion of plasma volume [19]
and thiazides might have beneficial effects on vascular resistance
[41].
Renal microvascular injury
The afferent arteriole, glomerulus and post-glomerular struc-
tures were relatively protected from injury throughout the
experiment: mild albuminuria developed by day 4 and was
further increased coincident with raised renal vascular resistance.
Our data suggest that protection from barotrauma reflects
maintenance of efficient autoregulation [42]. In contrast, injury
to the larger pre-glomerular resistance arteries was evident on the
amiloride-sensitive sodium reabsorption (DamilorideNa); D) the expression of the a subunit of the epithelial sodium channel (aENaC) normalized to
that of GAPDH. Measurements were made in cyp1a1-Ren2 transgenic rats, on either day 2 (n=9), 4 (n=9) or 8 (n=9) in the induction regimen. Non-
induced rats (n=8) served as control. E) mean arterial blood pressure (MABP) and F) fractional sodium excretion. Measurements were made in
cyp1a1-Ren2 transgenic rats receiving either vehicle (grey bar) or hydrochrorothaizide (hatched bar) by minipump. Data are mean 6 SE. Statistical
comparisons were made using ANOVA with Bonferroni post-test. P,0.001, **P,0.01, *P,0.05 versus the control group.
doi:10.1371/journal.pone.0036311.g004
Figure 5. 24-hour urinary excretion of albumin. Urine was
collected from conscious cyp1a1-Ren2 transgenic rats (n=8) maintained
in individual metabolism cages, over consecutive days of transgene
induction. Data are mean 6 SE. Statistical comparisons were made
using ANOVA with Bonferroni post-test. **P,0.01, *P,0.05 versus the
control day.
doi:10.1371/journal.pone.0036311.g005
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hypertensive range. Renal injury was consistent with vasospasm,
and might reflect damaging intermittent surges in systolic blood
pressure [43]. These were not visualized in our telemetry analysis
but data were only acquired hourly for short periods.
Pressure-independent renal injury, involving both angiotensin II
and aldosterone [44,45,46] is also possible. The extent of pressure-
independent renoprotection following RAAS inhibition is conten-
tious [47] as AT1R blockade has exacerbated organ damage in
some clinical trials [48]. Animal models suggest that transmission
of high pressure to the kidney drives vascular remodeling and
injury in angiotensin II-dependent hypertension [49,50]. Our data
show a protective effect of AT1R blockade, perhaps partially due
to losartan’s antihypertensive effect. However, chronic thiazide
therapy, which caused a similar fall in blood pressure, did not
abolish vascular injury, supporting a direct role for angiotensin II
in end-organ injury. The beneficial effects of spironolactone were
more clearly independent of blood pressure. Experimental and
clinical data suggest that aldosterone, some of which may be
synthesized in the kidney itself [51], is directly fibrogenic [52] and
can damage renal structures [53]. Aldosterone-induced podocyte
injury [54], for example, may explain the beneficial effect of
spironolactone on the albuminuria seen here.
Concluding Remarks
Renal, vascular and endocrine measurements have established
distinctive aetiologies of hypertensive and renovascular disease
following the conditional over-expression of renin in cyp1a1-Ren2
TGR. Our data show that angiotensin II, aldosterone and sodium
status act in concert to cause hypertension and renal impairment
and underscore the key role of thiazide-sensitive sodium transport
in the long-term regulation of blood pressure. Approximately 1/
3
rd of the blood pressure rise was resistant to thiazide or losartan
treatment. A similar proportion of hypertension persists in AT1R
null mice infused with angiotensin II [46], pointing to non-renal,
non-AT1R-mediated mechanisms. These may involve direct,
detrimental actions of renin on vascular function [55], sensitization
of the vasculature to vasoactive agents [23] and activation of the
sympathetic nervous system [56].
Materials and Methods
Ethics Approval
Experiments were performed under a UK Home Office Project
License and protocols were approved by The University of
Edinburgh. All surgery was performed under anaesthesia (details
are given under relevant sections, below) and all efforts were made
to minimize suffering.
Experiments were performed on male cyp1a1-Ren2 TGR on a
Fischer (F344) background, from a colony maintained in the
university’s animal house. Rats, aged 12–14 weeks, were given free
access to water and commercial rat chow, containing 0.3% sodium
by weight (Special Diet Services, UK) and were maintained under
controlled conditions of temperature (2161uC), humidity
(50610%) and light/dark (light 7am–7pm).
Blood pressure measurement in conscious rats
Radiotelemetry devices (Model TA 11PAC20, Data Sciences,
UK) were implanted into the thoracic aorta of Cyp1a1-Ren2 TGR
(n=5) under ketamine/medetomidine anaesthetic, with bupre-
norphine used as a reversal agent and analgesic. After recovery,
one-week equilibration was given during which restoration of the
circadian rhythms for blood pressures, activity and heart rate was
confirmed. Experimental data were then recorded and decoded
using Art 4.0 software (Data Sciences, UK).
Baseline readings were taken over four consecutive days and, on
day 5, the cyp1a1-Ren2 transgene was induced by administering the
naturally occurring xenobiotic, indole-3-carbinol (I3C; 100 mg/
kg/day in vegetable oil), by gastric gavage at 10am; this was
repeated on the following 6 days. Data were obtained on the hour,
processed to means, smoothed using a 5-point rolling average and
Figure 6. Temporal progression of microvascular injury in kidneys from cyp1a1-Ren2 transgenic rats. (A) After 1 day of transgene
activation myocycte vacuolation was observed in the media of the larger arteries (indicated by arrow). (B) After 3 days apoptotic nuclear fragments
were observed (arrow) and (C) there were areas of hemorrhage into necrotic foci. (D) After 7 days, vasculopathy was more extensive still and there
were foci of tubulointerstitial injury.
doi:10.1371/journal.pone.0036311.g006
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heart rate (for Figure 1). To analyze statistically periodicity, hourly
means were smoothed by 3
rd order local polynomial regression,
de-trended and analyzed using the x
2-periodogram algorithm
[57].
Renal function in anaesthetized rats
Separate cohorts of cyp1a1-Ren2 TGRs received I3C for either
1, 3 or 7 days; the control group (n=8) received an equivalent
volume of vegetable oil over a 7-day period. Time-points are
designated as control (n=8), day 2 (n=9); day 4 (=9) and day 8
(n=9). In each group, mean arterial blood pressure and renal
function were measured twenty-four hours after the final gavage
treatment, as follows. Following thiobutabarbital anaesthesia
(Inactin, 120 mg/kg IP; Sigma Aldrich UK), a cannula was
inserted into the right jugular vein through which a solution,
containing (in mmol/l): 120 NaCl, 10 LiCl, 15 NaHCO3 and 5
KCl, was infused (1 ml/h/100 g IV). The infusate also contained
0.5% p-amino hippuric acid (PAH) and 0.5% FITC-inulin. A
cannula, containing heparin-saline, was placed in the right carotid
artery for collection of blood and measurement of mean arterial
blood pressure. The bladder was catheterized for collection of
urine and a tracheostomy was performed to maintain a clear
airway.
One hour after the completion of surgery, rats underwent the
following protocol: three consecutive collections of urine were
made, each of 60 minutes. A sample (75 ml) of arterial blood was
drawn at the start and then after each urine collection period for
the measurement of haematocrit, FITC-inulin and PAH.
After the first urine collection, amiloride was administered
(2 mg/kg bolus; 2 mg/kg/h infusion). After the second urine
collection, hydrochlorothiazide was administered (2 mg/kg bolus;
2 mg/kg/h infusion) alongside the amiloride. The drugs were
delivered in a DMSO vehicle (2% v:v), which, in a separate group
of rats (n=7), had no effect on renal function or blood pressure
(data not shown). Finally, a 1 ml sample of arterial blood was
taken for measurement of plasma electrolytes and the kidneys
frozen at 280uC and used for Western blot. Animals were then
killed by an overdose of anaesthetic.
Analysis & calculations
The concentration of Na, K and Li in plasma and urine was
measured using ion-selective electrodes (Roche ISE, model 9180).
The effect of amiloride on sodium excretion was taken as the
difference between excretion rates in the first and second urine
collections; that of hydrochlorothiazide was taken as the difference
between excretion rates in the second and third urine collections.
FITC-inulin and PAH concentrations were measured as
described [4]. The clearance of PAH was taken as effective renal
plasma flow and used to calculate renal blood flow. Renal vascular
resistance was taken as the quotient of arterial blood pressure and
renal blood flow. Lithium clearance was used as an index of fluid
delivery to the end of the proximal tubule [26].
Urine collection in conscious rats
Cyp1a1-Ren2 transgenic rats (n=8) were housed individually in
metabolism cages with free access to powdered rat chow and
water. Rats were acclimatized and after a 4-day control period,
I3C was administered on each of 7 consecutive days, as described
above. Urine was collected every 24-hours. Albumin was
measured using commercial assays (Alpha Laboratories Ltd.,
UK), aldosterone by ELISA [58].
Interventional studies
Hydrochlorothiazide (4 mg/kg/d; n=6), spironolactone
(20 mg/kg/d; n=6) or losartan (10 mg/kg/d, n=6) were
administered by osmotic minipump (Alzet, Model 2ML1, Charles
River UK), implanted on day 0 under isofluorane anaesthesia. A
control group of rats (n=6) received vehicle (50% DMSO, 50%
saline) alone. After implant, the Ren2 transgene was induced over a
period of three days before being anesthetized for renal function
studies, as described. A three-day induction was selected as a time-
point at which significant changes to tubular function were not
associated with a decline in renal haemodynamics or major
destructive vascular lesions.
Western blot analysis
Total protein was extracted from one kidney by homogeniza-
tion and differential centrifugation in ice-cold buffer, containing
250 mM sucrose, 10 mM triethanolamine and 2% protease
inhibitor cocktail, pH 7.6 (Pierce Protein Research, Thermo-
scientific, UK). Protein solubilized in sample buffer (50 mg of total
protein per lane) was separated by SDS-PAGE and blotted to
PVDF membrane by semi-dry transfer. Immunoblotting was
Figure 7. Contributions to hypertension of AT1 and mineral-
ocorticoid receptors. A) Mean arterial blood pressure (MABP) and B)
hydrochlorthiazide-sensitive sodium reabsorption (DthiazideNa)i n
cyp1a1-Ren2 transgenic rats. Measurements were made in cyp1a1-
Ren2 transgenic rats, anaesthetized on day 4 of the experimental
regimen. The first control group (n=6; open bars) received vehicle, the
second control group (n=8; grey bars) received I3C to induce the Ren2
transgene. Experimental groups received I3C and either losartan (n=6;
grey hatched bars) or spironolactone (n=6; open hatched bars). Data
are means 6 SE and statistical comparisons were made using ANOVA
with Bonferroni post-test. ***P,0.001, **P,0.01, *P,0.05 versus the
non-induced control group and other comparisons as stated.
doi:10.1371/journal.pone.0036311.g007
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UK; 1:2500) and aENaC (Upstate, NY, USA; 1:2000) and
horseradish peroxide-conjugated secondary antibodies. Immuno-
detection was quantified by densitometry using ImageJ after
treatment of the blots with ECL reagents. Equal loading of total
protein was confirmed in the GAPDH (R&D Systems, UK;
1:5000) immunoblot.
Histopathologic analysis
Kidneys were immersion-fixed in 10% neutral buffered
formalin for 48 h followed by paraffin embedding. Four-micron
sections were examined blind by a Consultant Pathologist
(C.O.B.). Kidneys from at least three rats per experimental group
were examined. For each, 2 complete hemisections of the left
kidney were blocked and all vascular profiles in each hemisection
examined at 4 different levels in the block. Two were stained with
hematoxylin and eosin and two with Periodic Acid Schiff, giving 8
levels per case. Analysis of microvascular injury was performed
using an ordered categorical scale according the presence of
destructive microvascular arterial or arteriolar lesions character-
ized by intramural necrosis and/or fibrinoid change. A score of
‘‘one’’ indicates non-confluent necrosis and isolated myocyte
death; ‘‘two’’ indicates a single foci of necrosis per section; ‘‘three’’
indicates 2–3 foci; and ‘‘four’’ indicates .3 foci of destructive
vascular lesions. Undamaged sections were scored zero.
Statistics
Data are presented as mean 6 SE. Comparisons were made
using either one- or two-way analysis of variance, as appropriate:
post-hoc comparisons were made using the Holm-Sidak test. For
scoring of microvascular injury, contingency tables were generated
for X
2 analysis.
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